Thursday, July 08, 2010
Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric? -- Mason et al. 28 (20): 3234 -- Journal of Clinical Oncology
Anticancer drug coverage decisions that consider cost effectiveness are associated with greater restrictions and slower time to coverage. However, this approach may represent an explicit alternative to rationing achieved through the use of patient copayments.
Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch? -- Ng and Schrag 28 (20): 3207 -- Journal of Clinical Oncology
Note: this Editorial will be of interest to Lynch Syndrome families/patients
click here for link to paper: Filling the Gap: Development of the Oncology Nurse Practitioner Workforce
plus related article:
New line in your job description: Nurse Practitioner Educator
A growing number of states have passed legislation or instituted special agreements requiring health plans to pay the cost of routine medical care you receive as a participant in a clinical trial......
.......updated with information about Florida, Iowa, and South Carolina.
As of July 1, 2010, these states have implemented legislation or voluntary agreements requiring health plans to pay the cost of routine medical care for participants in certain clinical trials. More than 30 states now require such coverage through legislation or special voluntary agreements. View website…
Links on this page
* Use this map or this alphabetical list.
* Overview of the issue.
* Other resources.
add your opinions cancer oncology alternatives complimentary medicine Canada U.S. , insurance , options , patient website
"I stare at the primary care physician’s note in front of me. I have been concerned about our mutual patient’s hypertension. I believe it has been exacerbated by the use of bevacizumab, and I have referred her back for additional management. All I need is an acknowledgment of the problem and a treatment plan. The note that I have received is three pages long and is filled with unrelated laboratory values, scan results, and jumbled-up text....."
Disclosing a Diagnosis of Cancer: Where and How Does It Occur? -- Figg et al., 10.1200/JCO.2009.24.6389 -- Journal of Clinical Oncology
"Forty-four percent of patients reported discussions of 10 minutes or fewer..."
Physicians should disclose a cancer diagnosis in a personal setting, discussing the diagnosis and treatment options for a substantial period of time whenever possible.
Search of: ovarian cancer | Open Studies | received from 06/15/2010 to 07/07/2010 - List Results - ClinicalTrials.gov
Found 7 studies with search of: ovarian cancer | Open Studies | received from 06/15/2010 to 07/07/2010
1 Not yet recruiting Study of JI-101 in Patients With Advanced Head and Neck Cancers, Ovarian Cancers or K-RAS Mutant Colon Cancers
Conditions: Cancer; Head & Neck Cancer; Ovarian Cancer; Colon Cancer
Interventions: Drug: JI-101; Drug: Everolimus
2 Not yet recruiting Veliparib and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
3 Not yet recruiting Safety Study of MGAH22 in HER2-positive Carcinomas
Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
4 Recruiting GDC-0449 and RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Malignant Fibrous Histiocytoma of Bone; Gastrointestinal Stromal Tumor; Kidney Cancer; Malignant Conjunctival Neoplasm; Ovarian Cancer; Sarcoma; Small Intestine Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gamma-secretase inhibitor RO4929097
5 Recruiting Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Conditions: Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary Carcinoma
Interventions: Drug: temsirolimus; Drug: vinorelbine ditartrate
6 Recruiting Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
Intervention: Drug: Dexamethasone and recombinant hCG
7 Recruiting Effects of Exercise for Overweight Women With Polycystic Ovary Syndrome
Conditions: Polycystic Ovary Syndrome; Obesity
Interventions: Other: 16-week exercise training program; Other: Control Group without PCOS
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
The prevalence of BRCA1/2 mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA1/2 changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs.
BRCA1/2 somatic and germline mutations and expression loss are sufficiently common in ovarian cancer to warrant assessment for prediction of benefit in clinical trials of PARP1 inhibitors.